|
1.
|
Wilson JF: Liver cancer on the rise. Ann
Intern Med. 142:1029–1032. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2.
|
Merle P and Trepo C: Molecular mechanisms
underlying hepatocellular carcinoma. Viruses. 1:852–872. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
3.
|
Giannelli G and Antonaci S: Novel concepts
in hepatocellular carcinoma: from molecular research to clinical
practice. J Clin Gastroenterol. 40:842–846. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4.
|
Hanahan D and Weinberg RA: The hallmarks
of cancer. Cell. 100:57–70. 2000. View Article : Google Scholar
|
|
5.
|
Price JT and Thompson EW: Mechanisms of
tumour invasion and metastasis: emerging targets for therapy.
Expert Opin Ther Targets. 6:217–233. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
6.
|
Porter S, Clark IM, Kevorkian L and
Edwards DR: The ADAMTS metalloproteinases. Biochem J. 386:15–27.
2005. View Article : Google Scholar
|
|
7.
|
Kashiwagi M, Enghild JJ, Gendron C, Hughes
C, Caterson B and Itoh Y: Altered proteolytic activities of
ADAMTS-4 expressed by C-terminal processing. J Biol Chem.
279:10109–10119. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
8.
|
Bandtlow CE and Zimmermann DR:
Proteoglycans in the developing brain: new conceptual insights for
old proteins. Physiol Rev. 80:1267–1290. 2000.PubMed/NCBI
|
|
9.
|
Luque A, Carpizo DR and Iruela-Arispe ML:
ADAMTS1/METH1 inhibits endothelial cell proliferation by direct
binding and sequestration of VEGF165. J Biol Chem.
278:23656–23665. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10.
|
Hsu Y-P, Staton CA, Cross N and Buttle DJ:
Anti-angiogenic properties of ADAMTS-4 in vitro. Int J Exp Pathol.
93:70–77. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11.
|
Sharghi-Namini S, Fan HP, Sulochana KN,
Potturi P, Xiang W, Chong YS, Wang ZY, Wang H and Ge RW: The first
but not the second thrombospondin type 1 repeat of ADAMTS5
functions as an angiogenesis inhibitor. Biochem Biophys Res Commun.
371:215–219. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12.
|
Kuno K, Bannai K, Hakozaki M, Matsushima K
and Hirose K: The carboxyl-terminal half region of ADAMTS-1
suppresses both tumorigenicity and experimental tumor metastatic
potential. Biochem Biophys Res Commun. 319:1327–1333. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
13.
|
Held-Feindt J, Paredes EB, Blömer U,
Seidenbecher C, Stark AM, Mehdorn HM and Mentlein R:
Matrix-degrading proteases ADAMTS4 and ADAMTS5 (disintegrins and
metalloproteinases with thrombospondin motifs 4 and 5) are
expressed in human glioblastomas. Int J Cancer. 118:55–61. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
14.
|
Nagase H, Visse R and Murphy G: Structure
and function of matrix metalloproteinases and TIMPs. Cardiovasc
Res. 69:562–573. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15.
|
Lambert E, Dassé E, Haye B and Petitfrère
E: TIMPs as multi-facial proteins. Crit Rev Oncol Hematol.
49:187–198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
16.
|
Bugno M, Witek B, Bereta J, Bereta M,
Edwards DR and Kordula T: Reprogramming of TIMP-1 and TIMP-3
expression profiles in brain microvascular endothelial cells and
astrocytes in response to proinflammatory cytokines. FEBS Lett.
448:9–14. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17.
|
Laemmli UK: Cleavage of structural
proteins during the assembly of the head of bacteriophage T4.
Nature. 227:680–685. 1970. View
Article : Google Scholar : PubMed/NCBI
|
|
18.
|
Haddock G, Cross AK, Plum J, Surr J,
Buttle DJ, Bunning RAD and Woodroofe NM: Expression of ADAMTS-1,
-4, -5 and TIMP-3 in normal and multiple sclerosis CNS white
matter. Mult Scler. 12:386–396. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19.
|
Vandesompele J, De Preter K, Pattyn F,
Poppe B, Van Roy N, De Paepe A and Speleman F: Accurate
normalization of real-time quantitative RT-PCR data by geometric
averaging of multiple internal genes. Genome Biol. 3:Research 0034.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
20.
|
Pfaffl MW: A new mathematical model for
relative quantification in real-time RT-PCR. Nucleic Acids Res.
29:e452001. View Article : Google Scholar : PubMed/NCBI
|
|
21.
|
Nakashima T, Okuda K, Kojiro M, Jimi A,
Yamaguchi R, Sakamoto K and Ikari T: Pathology of hepatocellular
carcinoma in Japan. 232 consecutive cases autopsied in ten years.
Cancer. 51:863–877. 1983.PubMed/NCBI
|
|
22.
|
Illemann M, Bird NC, Majeed A, Lærum OD,
Lund LR, Danø K and Nielsen BS: Two distinct expression patterns of
urokinase, urokinase receptor and plasminogen activator inhibitor-1
in colon cancer liver metastases. Int J Cancer. 124:1860–1870.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
23.
|
Jones GC and Riley GP: ADAMTS proteinases:
a multi-domain, multi-functional family with roles in extracellular
matrix turnover and arthritis. Arthritis Res Ther. 7:160–169. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
24.
|
Liu YJ, Xu Y and Yu Q: Full-length
ADAMTS-1 and ADAMTS-1 fragments display pro- and antimetastatic
activity, respectively. Oncogene. 25:2452–2467. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
25.
|
Seals DF and Courtneidge SA: The ADAMs
family of metalloprotease: Multidomain proteins with multiple
functions. Genes Dev. 17:7–30. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
26.
|
Hu B, Kong LL, Matthews RT and Viapiano
MS: The proteoglycan brevican binds to fibronectin after
proteolytic cleavage and promotes glioma cell motility. J Biol
Chem. 283:24848–24859. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
27.
|
Darnton SJ, Hardie LJ, Muc RS, Wild CP and
Casson AG: Tissue inhibitor of metalloproteinase-3 (TIMP-3) gene is
methylated in the development of esophageal adenocarcinoma: Loss of
expression correlates with poor prognosis. Int J Cancer.
115:351–358. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
28.
|
Hashimoto G, Shimoda M and Okada Y:
ADAMTS-4 (aggrecanase-1) interaction with the C-terminal domain of
fibronectin inhibits proteolysis of aggrecan. J Biol Chem.
279:32483–32491. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
29.
|
Miyazaki T, Kato H, Nakajima M, Faried A,
Takita J, Sohda M, Fukai Y, Yamaguchi S, Masuda N, Manda R, Fukuchi
M, Ojima H, Tsukada K and Kuwano H: An immunohistochemical study of
TIMP-3 expression in oesophageal squamous cell carcinoma. Br J
Cancer. 91:1556–1560. 2004.PubMed/NCBI
|
|
30.
|
Ryder SD: Guidelines for the diagnosis and
treatment of hepatocellular carcinoma (HCC) in adults. Gut.
52:iii1–iii8. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31.
|
Berasain C, Castillo J, Prieto J and Avila
MA: New molecular targets for hepatocellular carcinoma: the ErbB1
signaling system. Liver Int. 153:174–185. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32.
|
Zimmers TA, McKillop IH, Pierce RH, Yoo J
and Koniaris LG: Massive liver growth in mice induced by systemic
interleukin 6 administration. Hepatology. 38:326–334. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
33.
|
Masui T, Hosotani R, Tsuji S, Miyamtot Y,
Yasuda S, Ida J, Nakajima S, Kawaguchi M, Koybayashi H, Koizuma M,
Toyoda E, Tulachan S, Arii S, Doi R and Imamura M: Expression of
METH-1 and METH-2 in pancreatic cancer. Clin Cancer Res.
7:3437–3443. 2001.PubMed/NCBI
|
